These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

883 related items for PubMed ID: 20137862

  • 21. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
    Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, François S, Berthou C, Gyan E, Milpied N, GOELAMS.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
    [Abstract] [Full Text] [Related]

  • 22. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN.
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [Abstract] [Full Text] [Related]

  • 23. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 24. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM.
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [Abstract] [Full Text] [Related]

  • 25. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [Abstract] [Full Text] [Related]

  • 26. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [Abstract] [Full Text] [Related]

  • 27. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [Abstract] [Full Text] [Related]

  • 28. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
    Chen CI, Abraham R, Tsang R, Crump M, Keating A, Stewart AK.
    Bone Marrow Transplant; 2001 Jan; 27(2):177-82. PubMed ID: 11281387
    [Abstract] [Full Text] [Related]

  • 29. Acute renal toxicity of 2 conditioning regimens in patients undergoing autologous peripheral blood stem-cell transplantation. Total body irradiation-cyclophosphamide versus ifosfamide, carboplatin, etoposide.
    Beyzadeoglu M, Arpaci F, Surenkok S, Ozyigit G, Oysul K, Caglar K, Ataergin S, Yenicesu M, Kaya A.
    Saudi Med J; 2008 Jun; 29(6):832-6. PubMed ID: 18521460
    [Abstract] [Full Text] [Related]

  • 30. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E.
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
    [Abstract] [Full Text] [Related]

  • 31. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 32. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma.
    Kato J, Mori T, Yokoyama K, Tsukada Y, Ueda T, Shimizu T, Okamoto S.
    Bone Marrow Transplant; 2011 Jul; 46(7):923-8. PubMed ID: 20972471
    [Abstract] [Full Text] [Related]

  • 34. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.
    Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E, GEL/TAMO Spanish Cooperative Group.
    Bone Marrow Transplant; 2001 Feb; 27(4):405-12. PubMed ID: 11313670
    [Abstract] [Full Text] [Related]

  • 35. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
    McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL.
    Bone Marrow Transplant; 2004 Jan; 33(1):19-24. PubMed ID: 14704653
    [Abstract] [Full Text] [Related]

  • 36. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.
    Gutierrez-Delgado F, Maloney DG, Press OW, Golden J, Holmberg LA, Maziarz RT, Hooper H, Buckner CD, Appelbaum FR, Bensinger WI.
    Bone Marrow Transplant; 2001 Sep; 28(5):455-61. PubMed ID: 11593318
    [Abstract] [Full Text] [Related]

  • 37. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
    Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A.
    Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
    [Abstract] [Full Text] [Related]

  • 38. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
    Martín A, Caballero MD, Pérez-Simón JA, López-Holgado N, Mateos MV, Cañizo MC, Miguel JF.
    Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049
    [Abstract] [Full Text] [Related]

  • 39. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [Abstract] [Full Text] [Related]

  • 40. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP, Stiff PJ, Toor AA, Parthasarathy M.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.